ANA FLORES, MD
Retina Specialist (Ophthalmology) Physician in MEMPHIS, Tennessee. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
ANA FLORES, MD reported a CMS MIPS final score of 75/100 — below the 83.1 national average — and filed 2,720 Medicare Part D claims in 2023.
- 75/100
- MIPS score · -8 vs avg
- 3K
- Part D claims, 2023
- 44%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
ANA FLORES, MD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
75 15th percentile higher than 15% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
ANA FLORES, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about ANA FLORES, MD?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Tennessee
How Retina Specialist (Ophthalmology) Physician compares to other specialties among Tennessee providers
Retina Specialist (Ophthalmology) Physician share within Tennessee
Retina Specialist (Ophthalmology) Physician is one of the more visible NUCC categories in Tennessee
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
ANA FLORES, MD's 2023 MIPS final score plotted against the Retina Specialist (Ophthalmology) Physician national average
- MIPS Final Score
- 75/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Retina Specialist (Ophthalmology) Physician) — 75/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Specialty volume Retina Specialist (Ophthalmology) Physician US NPIs
75/100 MIPS final score — 8.1 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Retina Specialist (Ophthalmology) Physician.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
ANA FLORES, MD appears in the CMS NPPES registry as a Retina Specialist (Ophthalmology) Physician provider holding MD credentials at 6029 WALNUT GROVE ROAD, MEMPHIS, TN, 38120, with a listed phone of (901) 747-3900. NPI 1346295565 was issued on 05/24/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what FLORES most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 2,720 prescription claims written by this provider, covering 548 Medicare beneficiaries and totaling roughly $776K in drug spend, split 56% brand-name and 44% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 75/100 for the 2023 performance year, compared with the national average of 83.1.
Retina Specialist (Ophthalmology) Physician is a narrow specialty nationwide, with 913 enrolled providers across 48 states and an average of 558 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1346295565 |
|---|---|
| Specialty | Retina Specialist (Ophthalmology) Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 05/24/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm ANA FLORES, MD's current license status, disciplinary history, and board certifications with the Tennessee Board of Medical Examiners in Tennessee before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for ANA FLORES, MD. Source: openpaymentsdata.cms.gov.
Total received
$1.5K
Largest payer
Regeneron Healthcare Solutions, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Brand-heavy
56% brand-name claims vs 44% generic, on 2,720 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 4,841
- Total Day Supply
- 138,141
- Brand vs Generic
- 56% brand / 44% generic
- Brand Drug Cost
- $732K
- Generic Drug Cost
- $44K
Patient Demographics
- Average Patient Age
- 73.1 years
- Avg HCC Risk Score
- 1.52
- Gender Split
- 61% female / 39% male
- Age Distribution
- <65: 74, 65-74: 239, 75-84: 173, 85+: 62
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What ANA FLORES, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Lumigan
Lumigan
330 claims
- Latanoprost
Latanoprost
269 claims
- Timolol Maleate
Timolol Maleate
231 claims
- Combigan
Combigan
223 claims
- Dorzolamide Hcl
Dorzolamide Hcl
212 claims
- Ofloxacin
Ofloxacin
200 claims
- Ciprofloxacin Hcl
Ciprofloxacin Hcl
187 claims
- Prednisolone Acetate
Prednisolone Acetate
158 claims
| Drug | Claims |
|---|---|
| Lumigan Bimatoprost | 330 |
| Latanoprost | 269 |
| Timolol Maleate | 231 |
| Combigan Brimonidine Tartrate/Timolol | 223 |
| Dorzolamide Hcl | 212 |
| Ofloxacin | 200 |
| Ciprofloxacin Hcl | 187 |
| Prednisolone Acetate | 158 |
| Alphagan P Brimonidine Tartrate | 114 |
| Restasis Cyclosporine | 110 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Retina Specialist (Ophthalmology) Physician Overview
How ANA FLORES, MD fits within the Retina Specialist (Ophthalmology) Physician landscape nationally.
ANA FLORES, MD's 2,720 claims are above the specialty average of 558.
Nearby Retina Specialist (Ophthalmology) Physician Providers in Tennessee
Other clinicians with the same primary specialty enrolled in Tennessee, drawn from the same CMS NPPES roster as FLORES.
Compare Retina Specialist (Ophthalmology) Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Tennessee
Frequently Asked Questions
What is ANA FLORES, MD's specialty? ▼
How much does ANA FLORES, MD prescribe under Medicare Part D? ▼
What is ANA FLORES, MD's Medicare quality score? ▼
Where is ANA FLORES, MD located? ▼
What is ANA FLORES, MD's NPI number? ▼
Does ANA FLORES, MD prescribe more brand-name or generic drugs? ▼
How many Retina Specialist (Ophthalmology) Physician providers are there in the US? ▼
What drugs does ANA FLORES, MD prescribe most often? ▼
Does ANA FLORES, MD accept Medicare? ▼
How can I verify ANA FLORES, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology